Biotech entity
The clearest coverage concentration is pharma: 5 of 6 stories, with the rest divided among 1 other category. Zacks Research is most often covered alongside Wall Street Zen, which appears in 5 of these 6 stories. Sentiment skews less negative than the wider beat, at 0% negative against 3% across all 62 Biotech stories in the same window.
Last mentioned: 2d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
The clearest coverage concentration is pharma: 5 of 6 stories, with the rest divided among 1 other category. Zacks Research is most often covered alongside Wall Street Zen, which appears in 5 of these 6 stories. Sentiment skews less negative than the wider beat, at 0% negative against 3% across all 62 Biotech stories in the same window. That works out to roughly 4.7 stories per week across a 9-day span. At 5, the average consequence score sits below the same-window beat average of 5.4. Each story carries 2 original sources on average, compared with 2.2 for the broader beat in this window. We currently track 6 Biotech stories that mention Zacks Research, published between August 4, 2026 and August 12, 2026.
Computed from the 6 stories linked to this entity, with beat comparisons drawn from all 62 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Zacks Research. Shared-story counts are live from our verified record — not editorial picks.
As the dominant landlord to pharma and startup labs, Alexandria’s FY 2026 EPS guidance of $6.35-$6.45—and its Q2 revenue beat of $662.78M—carry major implications for R&D real estate costs. While lease rates keep rising, a -36% net margin hints at stress in the sector that could eventually impact tenant concessions and space availability.
Source: dailypolitical.com · tickerreport.com
Analyst action pushes Talphera into the spotlight as a deeply undervalued biotech, with a $3.00 average target offering over 100% upside. Recent earnings beat and institutional buying add to the narrative. Two buy initiations from specialized firms highlight confidence in the pain management pipeline.
Source: themarketsdaily.com · dailypolitical.com
Spyglass Pharma's stock plunges to a new 52-week low of $17.56 despite a consensus 'Moderate Buy' rating and an average analyst target of $45. For biotech investors, the 156% upside potential must be weighed against a recent earnings miss and a downgrade to sell, raising questions about near-term pipeline catalysts.
Source: tickerreport.com · dailypolitical.com
Collegium Pharmaceutical's earnings beat of $0.20 per share, reaching $1.92 on $199.88M revenue, highlights its commercial success in the abuse-deterrent opioid space, a key sector for the biopharma industry.
Source: dailypolitical.com · themarketsdaily.com
Wall Street Zen upgraded biotech Agenus to buy despite a massive Q1 earnings miss, as the stock surged 189% from its 52-week low. Mixed analyst views and a $30 HC Wainwright target highlight the speculative upside in immuno-oncology.
Source: tickerreport.com · dailypolitical.com
Novavax was slapped with a sell rating by Wall Street Zen, even after beating Q1 revenue estimates by 49%. The downgrade highlights biotech skepticism toward small-cap vaccine players in a shifting market.
Source: dailypolitical.com · tickerreport.com
Zacks Research is linked from 6 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
